戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              PspA did not have to be attached to the bacterial surfac
2                                              PspA is a bifunctional protein that is directly involved
3                                              PspA is divided into two major families based on serolog
4                                              PspA is known to elicit protection against pneumococcal
5                                              PspA represents a major virulence factor and a promising
6                                              PspA therefore represses its own expression.
7                                              PspA was found to be specifically required for virulence
8                                              PspA was found to facilitate Mn(2+) transport by MntH an
9                                              PspA's C terminus has a choline-binding domain that anch
10                                              PspA, -B and -C regulate the bacterial phage shock prote
11                                              PspA, the most abundant of the Psp proteins, is required
12                                              PspA- and influenza virus-specific antibodies were detec
13                               Based on 1,352 PspA sequences derived from a pneumococcal carriage coho
14 mpared with incubation with an eluate from a PspA(-) strain.
15 hese results indicate an RASV synthesizing a PspA fusion protein representing both PspA families cons
16 t pneumococcal surface protein A (PspA) to a PspA-specific T hybridoma more efficiently than macropha
17 r CR4 (CR4(-/-)) were challenged with WU2, a PspA(+) capsular serotype 3 pneumococcus, and its PspA(-
18 of PPS14 and pneumococcal surface protein A (PspA) (PPS14-PspA) in saline was markedly defective.
19  as a fusion protein with surface protein A (PspA) (strains 603OVA(1) and Rx1Delta lytAOVA(1)) or wit
20 ted proteins pneumococcal surface protein A (PspA) and pneumococcal choline-binding protein C (PspC).
21 x domains of pneumococcal surface protein A (PspA) and pneumococcal surface protein C (PspC), to the
22              Pneumococcal surface protein A (PspA) and PspC are important virulence factors.
23              Pneumococcal surface protein A (PspA) and PspC of Streptococcus pneumoniae are surface v
24              Pneumococcal surface protein A (PspA) efficiently inhibits this bactericidal action.
25 al region of pneumococcal surface protein A (PspA) from S. pneumoniae strain A66.1 were cloned and ex
26              Pneumococcal surface protein A (PspA) has been shown to interfere with complement deposi
27              Pneumococcal surface protein A (PspA) is highly immunogenic and can induce a protective
28 detection of pneumococcal surface protein A (PspA) peptide and SP lysate from synthetic and actual hu
29  recombinant pneumococcal surface protein A (PspA) to a PspA-specific T hybridoma more efficiently th
30 al region of pneumococcal surface protein A (PspA) to the mouse immune system.
31 synthesizing pneumococcal surface protein A (PspA) were also confirmed to possess nearly complete lip
32 ch PPS14 and pneumococcal surface protein A (PspA) were stably attached to 1 mum (bacteria-sized) lat
33 juvant for a pneumococcal surface protein A (PspA) would enhance PspA-specific secretory-IgA Ab respo
34 that regard, pneumococcal surface protein A (PspA), a major surface protein of pneumococci, is a prom
35              Pneumococcal surface protein A (PspA), a major virulence factor of pneumococci, effectiv
36 pneumolysin, pneumococcal surface protein A (PspA), and pneumococcal surface antigen A (PsaA) were me
37 D and PhtE), pneumococcal surface protein A (PspA), plasminogen and fibronectin binding protein B (Pf
38 d immunogens pneumococcal surface protein A (PspA), putative proteinase maturation protein A (PpmA),
39  (PsaA), and pneumococcal surface protein A (PspA)-are currently being investigated as vaccine candid
40 induced by a pneumococcal surface protein A (PspA)-based nasal vaccine are necessary for prevention o
41  higher than pneumococcal surface protein A (PspA)-specific, genetic toxoid derivative of pneumolysin
42 ic region of pneumococcal surface protein A (PspA).
43 responses to pneumococcal surface protein A (PspA).
44 l surface by pneumococcal surface protein A (PspA).
45 regulated in trans by phage shock protein A (PspA).
46 ein with the pneumococcal surface protein A (PspA).
47 e for either pneumococcal surface protein A (PspA-), neuraminidase A (NanA-), or hyaluronidase (Hyl-)
48                Once this switch is activated PspA concentration increases, which might then allow it
49 resulted in reduced immune responses against PspA and Salmonella antigens.
50 us has a choline-binding domain that anchors PspA to the phosphocholine (PC) moieties on the pneumoco
51                     Both PspA/Rx1-EF5668 and PspA/EF5668-Rx1 were synthesized in the RASV and secrete
52 wo PspA fusion proteins, PspA/Rx1-EF5668 and PspA/EF5668-Rx1.
53 e presence of genes encoding PsaA, PpmA, and PspA in 11 clinical isolates was examined by PCR, and th
54 spA-specific CD4(+) T cell proliferative and PspA-induced Th1- and Th2- type cytokine responses were
55  cells and expressed both viral proteins and PspA.
56                   In general, both PsaA- and PspA-specific lung-, cervical lymph node-, nasal tract-,
57 ether, these findings suggest that PsaA- and PspA-specific mucosal responses as well as systemic humo
58          Using flow cytometry of PspA(+) and PspA(-) strains, we observed that the absence of PspA le
59                                         Anti-PspA antibody titers were inversely correlated to the le
60 0 were highly defective in eliciting an anti-PspA response, although the anti-polysaccharide response
61 ed strongly with both anti-PspA/Rx1 and anti-PspA/EF5668 antisera.
62 ion proteins reacted strongly with both anti-PspA/Rx1 and anti-PspA/EF5668 antisera.
63 enuation elicited significantly greater anti-PspA immune responses, including serum IgG and T cell se
64 in chi9241 induced significantly higher anti-PspA IgG and IgA antibody titers than strain chi9555, wh
65 lsed macrophages elicited an IgM or IgG anti-PspA and anti-polysaccharide response comparable in seru
66                                 The IgG anti-PspA response, in contrast to the IgG anti-polysaccharid
67  IgG responses without inducing mucosal anti-PspA IgA responses.
68 strains, mice produced robust levels of anti-PspA Abs and showed significantly improved survival agai
69 htly higher titers of mucosal and serum anti-PspA antibodies than P(pagC)-immunized mice, while titer
70 e strain delivering the pneumococcal antigen PspA, all of the mutations tested resulted in reduced im
71 +) plasmids specifying pneumococcal antigens PspA and PspC, respectively.
72 eric states permit formation of the apparent PspA-PspF dodecameric assembly, we conclude that PspA an
73 th 1 x 10(9) CFU of chi9760 (carrying Asd(+)-PspA and DadB(+)-PspC plasmids) elicited a dominant Th1-
74  the mixture of two strains, chi9828 (Asd(+)-PspA) and chi11026 (DadB(+)-PspC).
75 ructure represent major associations between PspA and lactoferrin.
76 idence for an interaction in E. coli between PspA and PspF in vivo, which strongly suggests that PspA
77                                         Both PspA/Rx1-EF5668 and PspA/EF5668-Rx1 were synthesized in
78                           PR regions of both PspA and PspC were antibody accessible on the pneumococc
79                       In the absence of both PspA and PspC, there is also a major increase in C1q-ind
80 zing a PspA fusion protein representing both PspA families constitutes an effective antipneumococcal
81 y regulated by PspF, negatively regulated by PspA, and induced in response to the production of secre
82 verse pneumococcal surface proteins A and C (PspA and PspC) and zinc metalloprotease A and B (ZmpA an
83 umococcal virulence factors include capsule, PspA, PspC, and Ply.
84 stead of uniformly covering the entire cell, PspA (and PspG) is highly organized into what appear to
85                          In uninduced cells, PspA, -B and -C were highly mobile and widely distribute
86 PspF binding-induced conformational changes, PspA may then share structural similarities with a bEBP
87               Under normal growth conditions PspA and PspD control the level of activity of ArcB/ArcA
88                   In non-inducing conditions PspA and PspF were almost exclusively in the soluble fra
89 of the cell, whereas under stress conditions PspA, PspD, and PspG deliver their effector functions at
90 enterobacteria, under non-stress conditions, PspA as a low-order assembly directly inhibits its cogna
91 B(CT) in the OFF state, whereas it contacted PspA in the ON state.
92 Vesicles isolated from this strain contained PspA in the lumen.
93                                 In contrast, PspA associates with the cytoplasmic membrane proteins P
94 ner membrane interacting negative controller PspA.
95  However, the PspC(CT).PspB(CT) and PspC(CT).PspA interactions were mutually exclusive in vitro.
96                        Using flow cytometry, PspA was found to be the major target of surface-bound c
97 t levels of C3 deposition were on a Deltaply PspA(-) PspC(-) mutant.
98 hat there was enhanced clearance of Deltaply PspA(-) PspC(-) pneumococci compared to the clearance of
99 rimary and secondary IgG anti-protein (i.e., PspA, PspC, and PsaA) response.
100              Single molecule imaging of eGFP-PspA and its amphipathic helices variants in live Escher
101 of BALB/c mice with RASV synthesizing either PspA fusion protein elicited serum immunoglobulin G (IgG
102               The amphipathic helices enable PspA to switch from a low-order gene regulator into an I
103 occal surface protein A (PspA) would enhance PspA-specific secretory-IgA Ab responses, which could pr
104            This was associated with enhanced PspA-specific CD4+-T-cell priming.
105  titers than strain chi9555, which expressed PspA constitutively.
106                  All RASV strains expressing PspA generated high antilipopolysaccharide antibody tite
107 tion on representative strains from all five PspA clades.
108 pF residue that is a binding determinant for PspA.
109 evels of serum immunoglobulin G specific for PspA and for outer membrane proteins from other enteric
110 high levels of serum antibodies specific for PspA as well as to Salmonella antigens in orally immuniz
111 high levels of serum antibodies specific for PspA as well as to Salmonella antigens.
112                                 Furthermore, PspA immunization significantly reduced secondary bacter
113                 Importantly, aged mice given PspA plus a combination of pFL and CpG ODN showed protec
114 duce adaptive immunity against heterologous (PspA of Streptococcus pneumoniae) and homologous antigen
115 hFcgammaRI Tg mice receiving anti-hFcgammaRI-PspA exhibited elevated S. pneumoniae-specific IgA, IgG2
116 argeted to hFcgammaRI as the anti-hFcgammaRI-PspA fusion, enhanced protection against lethal S. pneum
117                              Anti-hFcgammaRI-PspA or recombinant PspA (rPspA) alone was used to intra
118         Immune sera from the anti-hFcgammaRI-PspA-immunized Tg mice showed enhanced complement C3 dep
119 nsfusion responded with significantly higher PspA-specific antibody titers after immunization with Ps
120      These data provide new insight into how PspA and PspC act in synergy to protect pneumococci from
121                                     However, PspA is not required for the ability to tolerate secreti
122                                     However, PspA-specific mucosal IgA antibody levels were significa
123                 It is not known, however, if PspA and PspC affect IA.
124 -terminal amphipathic helices ahA and ahB in PspA HD1 are functional determinants involved in negativ
125 system normally leads to a large increase in PspA concentration and we found that this provided a sec
126 ses against vesicle components that included PspA and Salmonella-derived lipopolysaccharide and outer
127 onse, Psp protein levels increase, including PspA, which has been implicated as the master effector o
128 endent on PspBC but independent of increased PspA concentration.
129                      However, upon induction PspA, but not PspF, mainly associated with the membrane
130 chemical evidence showing that an inhibitory PspA-PspF regulatory complex, which has significantly re
131 required for the formation of the inhibitory PspA-PspF complex.
132 +) capsular serotype 3 pneumococcus, and its PspA(-) mutant JY1119.
133            These results indicate that HA-KO/PspA virus is a promising bivalent vaccine candidate tha
134 O/PspA virus, and mice inoculated with HA-KO/PspA virus were completely protected from lethal challen
135                   Although this virus (HA-KO/PspA virus) could replicate only in an HA-expressing cel
136 from mice intranasally inoculated with HA-KO/PspA virus, and mice inoculated with HA-KO/PspA virus we
137 x was prevented in mice immunized with HA-KO/PspA virus.
138      Real-time observations revealed lateral PspA and PspG complexes are highly mobile, but absent in
139                       At native TatA levels, PspA deficiency clearly affected anaerobic TMAO respirat
140                After inoculation by the LpxE/PspA strains, mice produced robust levels of anti-PspA A
141                                 Using mutant PspA(-) pneumococci of four different strains, we observ
142           Although IgA(-/-) mice given nasal PspA plus pFL had significantly high levels of PspA-spec
143 with a pneumococcal eluate containing native PspA, there was decreased deposition of CRP and C3 on th
144  mouse sera, we demonstrated that absence of PspA allows greater deposition of C1q and thus increased
145 ent C3 deposition realized in the absence of PspA alone and in the absence of PspA and PspC resulted
146  absence of PspA alone and in the absence of PspA and PspC resulted in both greatly increased IA to h
147 (-) strains, we observed that the absence of PspA led to exposure of PC, enhanced the surface binding
148  exhibit reduced viability in the absence of PspA when grown under metal-limited conditions.
149  MntH and ZupT was reduced in the absence of PspA.
150 can become growth limiting in the absence of PspA.
151                     The increased amounts of PspA and decreased rates of NADH oxidation in Delta tolC
152                                   Binding of PspA blocks surface accessibility of this bactericidal p
153       Further, a nasal vaccine consisting of PspA plus pFL effectively reduced pre-existing Streptoco
154          We investigated the contribution of PspA to Salmonella virulence.
155                      Using flow cytometry of PspA(+) and PspA(-) strains, we observed that the absenc
156 complex of the lactoferrin-binding domain of PspA with the N-lobe of human lactoferrin reveals direct
157 sh that all four putative helical domains of PspA are critical for the formation of the 36-mer.
158 putative N-terminal alpha-helical domains of PspA is crucial for the role of PspA as a negative regul
159  and PspF crucial for the negative effect of PspA upon PspF.
160 cosal IgA responses against both families of PspA.
161                 An 11-amino-acid fragment of PspA was also able to reduce the killing by LFN.
162 e the soluble recombinant N-terminal half of PspA could prevent killing by both ALF and LFN.
163                     The C-terminal halves of PspA and PspC have some structural similarity and contai
164                Despite the immunogenicity of PspA, PpmA, and PsaA, mice were still protected followin
165 st pneumococci and to decipher the impact of PspA on CR-dependent host defense, wild-type C57BL/6J mi
166  onto pneumococci, but to date the impact of PspA on CR-mediated host defense is unknown.
167 olish export result in a marked induction of PspA protein synthesis, consistent with its proposed rol
168 eraction, demonstrating that basal levels of PspA already interact with TatA.
169                        Significant levels of PspA-specific CD4(+) T cell proliferative and PspA-induc
170 pA plus pFL had significantly high levels of PspA-specific IgG Abs, high numbers of CFUs were detecte
171 juvant showed significantly higher levels of PspA-specific S-IgA and IgG Ab responses in both plasma
172  pFL and CpG ODN elicited elevated levels of PspA-specific secretory-IgA Ab responses in external sec
173  visualized the subcellular localizations of PspA (a negative regulator and effector of Psp) and PspG
174 sensitive linear region from 0 to 8 ng/mL of PspA peptide and a low limit of detection (LOD) of 0.218
175 stinct spatial and temporal organisations of PspA corresponding to its negative control and effector
176  protection-eliciting N-terminal portions of PspA and PspC.
177 his was associated with defective priming of PspA-specific CD4+ T cells.
178 detergents and observed a co-purification of PspA, a membrane-stress response protein.
179 eumoniae lysates consistent with the M(r) of PspA.
180 t, which lacks the choline-binding region of PspA, was added to the PspA(-) mutant.
181                        In many PR regions of PspA and PspC, there exists an almost invariant nonproli
182 y PspBC- and PspF-dependent up-regulation of PspA.
183 l domains of PspA is crucial for the role of PspA as a negative regulator of PspF.
184 omologue, VIPP1, indicating that the role of PspA in Tat export may be phylogenetically conserved.
185                    The physiological role of PspA recruitment to TatA may therefore be the control of
186 basis for exploring the specialised roles of PspA homologues such as YjfJ, LiaH and Vipp1.
187                             Prior studies of PspA and PspC as immunogens focused primarily on the alp
188 ns between the negatively charged surface of PspA helices and the highly cationic lactoferricin moiet
189 murium displaying the variable N terminus of PspA (alpha1alpha2) for intranasal vaccination, which in
190 ever, studies on VIPP1 itself, as well as on PspA, its bacterial homolog, suggests that this protein
191 rotection than PspA/EF5668-Rx1, PspA/Rx1, or PspA/EF5668.
192 ed with the Synechocystis sp. strain PCC6803 PspA homologue, VIPP1, indicating that the role of PspA
193 ion between integral (PspBC) and peripheral (PspA) cytoplasmic membrane proteins and a soluble transc
194                                   Also, Ply, PspA, and PspC expression resulted in C3 degradation in
195              A fragment of the S. pneumoniae PspA gene was cloned and sequenced, and the deduced amin
196  assessment and the Streptococcus pneumoniae PspA protein for validation of our system in mice.
197 al surface antigen, Streptococcus pneumoniae PspA, with a similar proline-rich region.
198 e to beads coated simultaneously with PPS14+[PspA] peaked rapidly, with the secondary response highly
199      Beads coated simultaneously with PPS14+[PspA], similar to conjugate, induced in mice boosted PPS
200 pneumococcal surface protein A (PspA) (PPS14-PspA) in saline was markedly defective.
201 y linked to each other, in contrast to PPS14-PspA conjugate.
202 ntrast, immunization of aged mice with PPS14-PspA combined with an unmethylated CpG-containing oligod
203                 To provide broad protection, PspA proteins from pneumococcal strains Rx1 (family 1) a
204 nserved membrane-associated effector protein PspA has four alpha-helical domains (HD1-HD4) and helps
205 zed a derivative of the pneumococcal protein PspA engineered to be secreted into the periplasmic spac
206  expressing the pneumococcal surface protein PspA from an Asd(+) balanced-lethal plasmid.
207 the Streptococcus pneumoniae surface protein PspA from an Asd(+)-balanced lethal plasmid.
208 yla reveal conservation of only one protein, PspA.
209 ely regulated by another regulatory protein, PspA.
210 tide peptidase (SppA), phage shock proteins (PspA and YvlC, a PspC homologue) and tellurite resistanc
211 e combined to form two PspA fusion proteins, PspA/Rx1-EF5668 and PspA/EF5668-Rx1.
212   We establish that a stable repressive PspF-PspA complex is located in the nucleoid, transiently com
213 mmunized with an equivalent dose of purified PspA.
214 , while control mice immunized with purified PspA or empty vesicles were not protected.
215 hibition was not observed when a recombinant PspA fragment, which lacks the choline-binding region of
216          Anti-hFcgammaRI-PspA or recombinant PspA (rPspA) alone was used to intranasally immunize wil
217 (i.d.) immunization of mice with recombinant PspA in combination with LT-IIb(T13I), a novel i.d. adju
218 exists in an OFF state, which cannot recruit PspA, or an ON state, which can.
219 tion to its transcriptional inhibitory role, PspA assists maintenance of the proton motive force and
220 lical domain of Streptococcus pneumoniae Rx1 PspA was cloned into pYA3681, resulting in pYA3685 to te
221 tly greater protection than PspA/EF5668-Rx1, PspA/Rx1, or PspA/EF5668.
222  adoptive basophil transfer before secondary PspA immunization.
223 ions yielded the largest amounts of secreted PspA and PspC, respectively, and induced the highest ser
224 composed of around six PspF subunits and six PspA subunits, suggesting that PspA exists in at least t
225                                    Up to six PspA subunits suppress PspF hexamer action.
226 nstitute a regulatory switch that moves some PspA to the membrane when an inducing trigger is encount
227 ort of volunteers we assessed 6BPS-specific, PspA-specific, and PspC-specific IgG and IgA plasma and
228                                Subsequently, PspA-specific antibody titers and resistance of mice aga
229 a from mice immunized with RASV synthesizing PspA/Rx1-EF5668 bound to the surface and directed C3 com
230 enterotoxin family, elicited strong systemic PspA-specific IgG responses without inducing mucosal ant
231    PspB and PspC were important for the TatA-PspA contact.
232 icited significantly greater protection than PspA/EF5668-Rx1, PspA/Rx1, or PspA/EF5668.
233 ion after influenza virus infection and that PspA immunization mitigates early secondary pneumococcal
234 nity against pneumococcal infection and that PspA interferes with the protective role of the alternat
235 -PspF dodecameric assembly, we conclude that PspA and PspF demonstrate a strong propensity to self-as
236                     Here we demonstrate that PspA and PspG directly confront a variety of inducing st
237   We used flow cytometry to demonstrate that PspA was readily detectable on the surface of the pneumo
238 s is independent of PspBC, establishing that PspA and PspF can function as a minimal Psp system respo
239   Here, we present biochemical evidence that PspA engages across the side of a PspF hexameric ring.
240 lowed us to obtain unequivocal evidence that PspA is not required for secretin-stress tolerance.
241                   Our findings indicate that PspA contributes to secondary S. pneumoniae infection af
242 ral lines of in vitro evidence indicate that PspA-PspF interactions inhibit the ATPase activity of Ps
243 st direct evidence supporting the model that PspA switches binding partners from PspF to PspBC upon i
244  of four different strains, we observed that PspA offers significant protection against killing by AL
245     By structural modelling, we propose that PspA binds to PspF via its first two helical domains.
246                              We propose that PspA promotes Salmonella virulence by maintaining proton
247         It has previously been proposed that PspA evenly coates the inner membrane of the cell.
248 - and GFP-tagged proteins also revealed that PspA colocalizes with PspB and PspC into large stationar
249                           This revealed that PspA, -B and -C share common behaviours, including a str
250 f Firmicutes and Actinobacteria reveals that PspA orthologs associate with non-orthologous regulatory
251                      These results show that PspA-based vaccine-induced specific S-IgA Abs play a nec
252          These results strongly suggest that PspA plays a major role in mediating the immunosuppressi
253            Together, these data suggest that PspA, -B and -C do not stably interact and are highly mo
254 units and six PspA subunits, suggesting that PspA exists in at least two different oligomeric assembl
255 e confounding and disputable suggestion that PspA is not involved in mitigating secretin toxicity.
256 d PspF in vivo, which strongly suggests that PspA-directed inhibition of PspF occurs via an inhibitor
257                                          The PspA protein is distributed between the cytoplasm and th
258                                          The PspA/Rx1-EF5668 protein elicited significantly greater p
259 ble to specifically recognize and detect the PspA peptide mixed with other physiologically relevant c
260 tivator protein PspF was not involved in the PspA-TatA interaction, demonstrating that basal levels o
261 ng important surface proteins, including the PspA virulence factor, two proteins (Spr0096 and Spr1875
262 without prior influenza virus infection, the PspA- mutant exhibited attenuation both in mice with and
263 ermined that the high-level induction of the PspA stress protein under YidC depletion conditions is r
264 virus-infected mice, for which growth of the PspA- mutant was 1800-fold lower than that of the parent
265 here was much greater C3 deposition onto the PspA(-) pneumococcus when exposed to normal mouse serum
266  serum, and more iC3b was deposited onto the PspA(-) than the PspA(+) strain.
267 iC3b was deposited onto the PspA(-) than the PspA(+) strain.
268                 Here we established that the PspA negative regulation of PspF ATPase activity is the
269 ine-binding region of PspA, was added to the PspA(-) mutant.
270                           Moreover, when the PspA(-) mutant was incubated with a pneumococcal eluate
271                                   Therefore, PspA is probably an effector that may play a role in mai
272 te PspF inhibition to occur, more than three PspA subunits need to bind a PspF hexamer with at least
273 indings suggested that the binding of ALF to PspA probably blocks the active site(s) of ALF that is r
274 passively or actively acquired antibodies to PspA or type 3 PS were equivalently protected from homol
275                                  Antibody to PspA enhanced killing by lactoferrin.
276 lysin but no change in titers of antibody to PspA.
277 Salmonella components, while the response to PspA was less apparent in most mice.
278 rations of IgG and IgA antibody responses to PspA and PdB (a recombinant toxoid derivative of pneumol
279 937(pYA3685) developed antibody responses to PspA and Salmonella outer membrane proteins.
280 etained the same IgG titer level in serum to PspA, a test antigen from Streptococcus pneumoniae, and
281 ys excellent electrochemical activity toward PspA with a sensitive linear region from 0 to 8 ng/mL of
282  EF5668 (family 2) were combined to form two PspA fusion proteins, PspA/Rx1-EF5668 and PspA/EF5668-Rx
283                                        Using PspA and/or PspC isogenic mutants and complement-deficie
284 ly communicating with the inner membrane via PspA.
285 e levels of 6BPS IgG in serum or nasal wash, PspA-specific, or PspC-specific memory B cells or plasma
286 WT mice in the absence of adjuvant, but when PspA was targeted to hFcgammaRI as the anti-hFcgammaRI-P
287 tion mutants further supported a model where PspA is predominantly membrane associated only when the
288 sp system comprises seven proteins, of which PspA is the central component.
289              Our results indicate that while PspA could serve as a target of these protective antibod
290  and in which priming could be achieved with PspA alone.
291 played TatA complexes in direct contact with PspA.
292 PspC (PspC(CT)) that interacts directly with PspA, both in vivo and in vitro.
293                      Nasal immunization with PspA plus a combination of pFL and CpG ODN elicited elev
294 into mice before secondary immunization with PspA significantly protected mice from lethal IPD.
295 ific antibody titers after immunization with PspA.
296                  Mice nasally immunized with PspA plus a plasmid expressing Flt3 ligand (pFL) cDNA as
297 tor PspF is inhibited by an interaction with PspA.
298 H protease and an interaction interface with PspA, both of which would be compatible with its newly p
299 s 603OVA(1) and Rx1Delta lytAOVA(1)) or with PspA, neuraminidase A, and pneumolysin (Rx1Delta lytAOVA
300 this study, we characterize sequences within PspA and PspF crucial for the negative effect of PspA up

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top